Opinion: How the FDA bent its rules for Biogen’s Alzheimer’s drug and why that’s bad for the entire...
The FDA’s stunning accelerated approval for Biogen’s Alzheimer’s drug Aduhelm, with limited clinical evidence supporting the decision, will have repercussions across the entire biopharma industry....
endpoints.news